Healthcare - Drug Manufacturers - Specialty & Generic - NASDAQ - US
$ 0.259
-4.18 %
$ 2.59 M
Market Cap
-0.04
P/E
CASH FLOW STATEMENT
-7.63 M
OPERATING CASH FLOW
0
INVESTING CASH FLOW
11.5 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Petros Pharmaceuticals, Inc.
| Net Income | -8.16 M |
| Depreciation & Amortization | 3.42 M |
| Capital Expenditures | -1 |
| Stock-Based Compensation | 417 K |
| Change in Working Capital | 625 K |
| Others | -3.33 M |
| Free Cash Flow | -7.63 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | |
|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | ||||||
| Net Income | (8.2) | (20.0) | (9.0) | (20.6) | (32.5) | (32.5) |
| Depreciation & Amortization | 3.4 | 5.6 | 6.9 | 6.7 | 5.3 | 8.1 |
| Deferred Income Tax | 0 | 0 | (9.5) | (1.4) | (0.6) | 6.94 K |
| Stock Based Compensation | 0.4 | 1.2 | 1.3 | 0 | 0 | 0 |
| Other Operating Activities | (3.9) | 3.7 | 0.2 | 2.0 | 11.9 | 42.5 |
| Change in Working Capital | 0.6 | (3.3) | (1.8) | (5.6) | 13.1 | 4.9 |
| Cash From Operations | (7.6) | (12.8) | (11.9) | (15.3) | 2.5 | 8.0 |
| INVESTING CASH FLOW | ||||||
| Capital Expenditures | 1 | 0 | 0 | 4.63 K | 71.5 K | (1.9) |
| Other Items | 1 | 0 | 0 | 0 | 0 | 0 |
| Cash From Investing Activities | 0 | 0 | 0 | 4.63 K | 71.5 K | (1.9) |
| FINANCING CASH FLOW | ||||||
| Common Stock Repurchased | (2.0) | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | (1.5) | (1.6) | (7.2) | 8.8 | (3.1) | (2.5) |
| Dividends Paid | (556.7) | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 567.7 | 0 | 4.0 | 21.5 | (2.9) | 0 |
| Cash From Financing Activities | 11.5 | (1.6) | 18.6 | 30.3 | (3.1) | (2.5) |
| CHANGE IN CASH | ||||||
| Net Change In Cash | 3.9 | (14.4) | 6.7 | 15.0 | (0.6) | 3.6 |
| FREE CASH FLOW | ||||||
| Free Cash Flow | (7.6) | (12.8) | (11.9) | (15.3) | 2.5 | 6.1 |